Etanercept in psoriatic arthritis: Sustained improvement in skin and joint disease and inhibition of radiographic progression at 2 years - 21/08/11
Mark Lebwohl, MD, Mount Sinai School of Medicine, New York, NY, United States; Alice Gottlieb, MD, PhD, University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical Center, New Brunswick, NJ, United States; Bernard S. Goffe, MD, Minor & James Medical, P.L.L.C., Seattle, WA, United States; Angelika Jahreis, MD, PhD, Amgen Inc., Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. P2753 Dr. Lebwohl has received grant funding from Amgen and Wyeth and is an investigator and consultant for these companies; he has also received an honorarium. Dr. Gottlieb is a consultant, investigator, and speaker for Amgen. Dr. Goffe is a speaker and consultant for Amgen and provided support for the research. Research funded by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth Research |
Vol 52 - N° 3S
P. P184 - mars 2005 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?